Guidehouse’s Outlook emphasizes that pharmaceutical commercialization is moving toward a model of extreme personalization and agility to navigate a care ecosystem defined by specialty therapies and complex provider structures. The strategy focuses on evolving direct-to-consumer engagement into personalized service platforms, scaling AI as a core operational budget line rather than just a prototype, and utilizing real-world evidence as a primary differentiator. Additionally, leaders must adapt to a shift from vertical to horizontal integration, requiring reengineered market access and patient support functions to effectively engage with non-hospital sites of care. Responsory’s takeaway: Brands that continue treating DTC as promotion, AI as experimentation, and RWE as supplementary will find themselves outmaneuvered by competitors who’ve reengineered these functions as core commercial drivers.
Subscribe
Get the Newsletter
<INSERT HUBSPOT CODE>
Recent
